Beacon Pharmaceuticals Statistics

Total Valuation

Beacon Pharmaceuticals has a market cap or net worth of BDT 31.53 billion. The enterprise value is 38.37 billion.

Market Cap	31.53B
Enterprise Value	38.37B

Important Dates

The last earnings date was Sunday, December 15, 2024.

Earnings Date	Dec 15, 2024
Ex-Dividend Date	Oct 28, 2024

Share Statistics

Beacon Pharmaceuticals has 231.00 million shares outstanding.

Current Share Class	n/a
Shares Outstanding	231.00M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	39.87%
Owned by Institutions (%)	0.33%
Float	138.91M

Valuation Ratios

The trailing PE ratio is 61.57.

PE Ratio	61.57
Forward PE	n/a
PS Ratio	2.82
PB Ratio	4.89
P/TBV Ratio	4.91
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	74.93
EV / Sales	3.43
EV / EBITDA	n/a
EV / EBIT	19.22
EV / FCF	-81.87

Financial Position

The company has a current ratio of 1.44, with a Debt / Equity ratio of 1.58.

Current Ratio	1.44
Quick Ratio	0.68
Debt / Equity	1.58
Debt / EBITDA	n/a
Debt / FCF	-21.78
Interest Coverage	1.72

Financial Efficiency

Return on equity (ROE) is 8.02% and return on invested capital (ROIC) is 8.15%.

Return on Equity (ROE)	8.02%
Return on Assets (ROA)	7.18%
Return on Capital (ROIC)	8.15%
Revenue Per Employee	2.69M
Profits Per Employee	123,040
Employee Count	3,872
Asset Turnover	0.64
Inventory Turnover	2.27

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -44.29% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-44.29%
50-Day Moving Average	123.41
200-Day Moving Average	158.21
Relative Strength Index (RSI)	62.68
Average Volume (20 Days)	125,532

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Beacon Pharmaceuticals had revenue of BDT 11.18 billion and earned 512.09 million in profits. Earnings per share was 2.22.

Revenue	11.18B
Gross Profit	5.88B
Operating Income	2.00B
Pretax Income	958.75M
Net Income	512.09M
EBITDA	n/a
EBIT	2.00B
Earnings Per Share (EPS)	2.22

Full Income Statement

Balance Sheet

The company has 3.37 billion in cash and 10.21 billion in debt, giving a net cash position of -6.84 billion or -29.60 per share.

Cash & Cash Equivalents	3.37B
Total Debt	10.21B
Net Cash	-6.84B
Net Cash Per Share	-29.60
Equity (Book Value)	6.45B
Book Value Per Share	27.93
Working Capital	4.08B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 351.26 million and capital expenditures -819.95 million, giving a free cash flow of -468.69 million.

Operating Cash Flow	351.26M
Capital Expenditures	-819.95M
Free Cash Flow	-468.69M
FCF Per Share	-2.03

Full Cash Flow Statement

Margins

Gross margin is 52.61%, with operating and profit margins of 17.85% and 4.58%.

Gross Margin	52.61%
Operating Margin	17.85%
Pretax Margin	8.57%
Profit Margin	4.58%
EBITDA Margin	n/a
EBIT Margin	17.85%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 2.00, which amounts to a dividend yield of 1.47%.

Dividend Per Share	2.00
Dividend Yield	1.47%
Dividend Growth (YoY)	25.00%
Years of Dividend Growth	n/a
Payout Ratio	71.38%
Buyback Yield	n/a
Shareholder Yield	1.47%
Earnings Yield	1.62%
FCF Yield	-1.49%

Dividend Details

Stock Splits

The last stock split was on November 27, 2011. It was a forward split with a ratio of 1.05.

Last Split Date	Nov 27, 2011
Split Type	Forward
Split Ratio	1.05

Scores

Beacon Pharmaceuticals has an Altman Z-Score of 3.43.

Altman Z-Score	3.43
Piotroski F-Score	n/a